Savolitinib and Durvalumab for Metastatic Papillary Renal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)
J. Clin. Oncol 2023 Feb 21;[EPub Ahead of Print], C Suárez, JMG Larkin, P Patel, BP Valderrama, A Rodriguez-Vida, H Glen, F Thistlethwaite, C Ralph, G Srinivasan, MJ Mendez-Vidal, R Hartmaier, A Markovets, A Prendergast, B Szabados, K Mousa, T PowlesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.